Drug recall · May 17, 2023
Atovaquone Oral Suspension USP recall
Why: Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured by: Hetero Labs Limited, Jeedimetla, Hyderabad - 500 055, India, NDC# 31722-629-21.
- Lots / codes
Lot# E220182, Exp. 12/31/2023
- Quantity
- 1568 bottles
- Company
- Camber Pharmaceuticals Inc., Piscataway, NJ
- Distribution
- Nationwide in the USA
- Initiated
- March 13, 2023 · Voluntary: Firm initiated
- Classified
- May 8, 2023
- Reported
- May 17, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Atovaquone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.